Several reports have noted that individuals with NSCLC whose tumors are documented to contain a mutation in the EGFR receptor have a substantially greater chance of responding to small-molecule ...

Oct. 7, 2005 — The U.S. Food and Drug Administration (FDA) has approved an assay for the detection of epidermal growth factor receptor mutations in patients with non-small cell lung cancer; a D-dimer ...

Afatinib almost doubled progression-free survival versus chemotherapy in advanced lung cancer with uncommon EGFR mutations. The treatment effect was consistent across major uncommon mutations, ...

Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells become highly resistant to treatment after developing mutations in a key gene ...

SAN DIEGO--(BUSINESS WIRE)--Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Precision Drug Development, today announced findings from a study using the Cellworks Platform ...

16.0 months median progression-free survival (mPFS) with firmonertinib indicates strong efficacy in first-line patients with EGFR PACC mutant non-small cell lung cancer (NSCLC). Robust central nervous ...

Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC Emerging data show non-classical EGFR mutations can be co-expressed with the classical L858R ...

Hematoxylin and eosin staining revealed poorly differentiated carcinoma with round cells and rhabdoid morphology (A, 100×). Positive expression of CK5/6 (B, 100×) and CK7 (C, 100×). Suggestive SMARCA4 ...

AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC EGFR ...

Retrospective review of 33,850 molecularly profiled ovarian cancer samples from real-world patients who underwent next-generation sequencing (NGS) of DNA between 2016 and 2025. EGFR-mutated cases were ...